Compare ADMA Biologics Inc (ADMA) vs MGM Resorts International (MGM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs MGM Resorts International — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while MGM Resorts International trades at $46.38 (market cap $11.93B). The key difference: MGM Resorts International is far larger — about 5.6× ADMA Biologics Inc's market cap, and MGM Resorts International pays a 0.03% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | MGM | |
|---|---|---|
Market Cap | $2.13B | $11.93B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $50.69 |
52-Week Low | $7.60 | $30.72 |
Enterprise Value | $2.20B | $40.98B |
Dividend Yield | — | 0.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
MGM Resorts International (MGM) trades at $46.64, down 0.98% on the day, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q1 2026 EPS of $0.49, slightly missing expectations, while Q4 2025 saw a significant beat. Revenue growth has been steady, reaching $17.54B in 2025, though net income margins have compressed to 1.03%. Recent news highlights a potential acquisition offer from Barry Diller at $48.30 per share, under investigation by BFA Law.
The outlook for MGM is cautiously optimistic, supported by analyst consensus leaning Buy (48.64%) and a price target of $45.45. Opportunities include strategic partnerships and digital expansion via BetMGM, but risks persist from high debt levels, regulatory scrutiny, and volatile earnings performance. Investors should weigh the acquisition premium against fundamental valuation metrics like a high P/E of 64.22.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →
